Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 1/20 | 0.64 |
| ▸ | CCR4 | P51679 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631417 | 0.78 | EDNRA (1.00) | EDNRA | |
| SCHEMBL7228577 | 0.77 | EDNRB (0.61) | EDNRAALDH1A1 | |
| SCHEMBL27508435 | 0.76 | EDNRA (0.50) | EDNRAKMT2ATP53MEN1 | |
| SCHEMBL4632351 | 0.74 | EDNRB (0.56) | EDNRAALDH1A1TP53 | |
| SCHEMBL7342871 | 0.73 | EDNRB (0.64) | EDNRAALDH1A1TSHR | |
| SCHEMBL7849845 | 0.73 | EDNRA (0.43) | EDNRA | |
| SCHEMBL6151621 | 0.73 | EDNRB (0.64) | EDNRAALDH1A1TSHR | |
| SCHEMBL7346002 | 0.72 | EDNRA (0.76) | EDNRAKMT2ATSHRMEN1 | |
| SCHEMBL6968888 | 0.72 | EDNRA (0.76) | EDNRAKMT2ATSHRMEN1 | |
| SCHEMBL7858704 | 0.72 | EDNRB (0.48) | EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541498-B2 | Antiinflammatory agents, antiasthmatics | TEXAS BIOTECHNOLOGY | 2003-04-01 | — | — | US | claimed |
| US-20010036958-A1 | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | claimed |
| US-5591761-A | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-01-07 | — | — | US | claimed |
| EP-0980369-B1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | ENCYSIVE PHARMACEUTICALS INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1498418-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1498419-A1 | Process for preparing alkali metal salts of hydrophobic sulfonamides | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6613804-B2 | Treatment of hypertension, cardiovascular disease, pulmonary hypertension, erythropoietin-mediated vasoconstriction, endotoxin shock, pulmonary hypertension, anaphylactic shock and hemorrhagic shock | ENCYSIVE PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | disclosed |
| EP-0819125-B1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORP (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020095041-A1 | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-18 | — | — | US | disclosed |
| US-6342610-B2 | COMPOUNDS SUCH AS N-(4-BROMO-3-METHYL-5-ISOXAZOLYL)-2-N-BENZYLBENZO(B)THIOPHENE-3-SUFONAMIDE ADMINISTERED AS ENDOTHELIN PEPTIDE RECEPTOR ANTAGONISTS | TEXAS BIOTECHNOLOGY CORP. | 2002-01-29 | — | — | US | disclosed |
| US-6331637-B1 | N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION | 2001-12-18 | — | — | US | disclosed |
| EP-0699191-B1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORP (US) | 1998-12-16 | — | — | EP | disclosed |
| EP-0870764-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0819125-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-01-21 | — | — | EP | disclosed |
| US-5594021-A | VASOCONSTRICTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| US-5591761-A | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-01-07 | — | — | US | disclosed |
| US-5571821-A | CARDIOVASCULAR DISORDERS TO MODULATE ENDOTHELIN, HYPOTENSIVE AGENTS AND VASOCONSTRICTION | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1996031492-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0699191-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095041-A1 | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRB, EDNRA, ECE2 | EDNRA 2/4885CCR4 2977/4885KDM4E 1668/4885 |
| US-20010036958-A1 | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | EDNRB, EDNRA, ECE1 | EDNRA 2/4885CCR4 2916/4885KDM4E 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.